Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N)
J. Wanders(Eisai (United Kingdom)), A.-R. Hanauske(KU Leuven), Stuart Kaye(University of Wollongong), M. Lehnert(Unknown), Paul Wissel(University of Pennsylvania), Robert Paridaens(Cornell University), W.W. ten Bokkel Huinink, C. Sessa(Vita-Salute San Raffaele University), Martine Piccart(Université Libre de Bruxelles), Nikolaos Pavlidis(University Hospital of Ioannina)
Cited by 3
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k